The Medicines Company (MDCO)

Company Description

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in cardiovascular events such PTCA and stenting; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent that is Phase III clinical trial for the prevention of platelet activation; Oritavancin, an investigational intravenous antibiotic, which is in Phase III clinical trials for the treatment of acute bacterial infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. Products under development include MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; and ALN-PCS, a development program for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular, neurocritical care, and serious infection therapeutic areas; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP.

 

 

COMPANY ADDRESS
The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 U.S.A
United States

COMPANY PHONE
973-290-6000
Toll-free: 800-388-1183

COMPANY WEBSITE



Get BioInvest's perspective on the Medicines Company's CEO


Latest Company News

The Medicines Company (MDCO) Shouts Loudly With Its Technical Chart NY Stock News - 9 hours ago The technicals for The Medicines Company (MDCO) have taken shape, and with them a comprehensive picture has emerged. This is the current state of play as presented by the current technical setup. [...]
Thu, Apr 27, 2017 8:26:00 PM, Continue reading at the source
2 Stocks to keep an eye on Today: The Medicines Company (MDCO), SM Energy ... StockNewsJournal - 15 hours ago The Medicines Company (NASDAQ:MDCO) market capitalization at present is $3.55B at the rate of $49.75 a share. The firm's price-to-sales ratio was noted 20.89 in contrast with an overall industry average of 3.67. [...]
Thu, Apr 27, 2017 2:48:00 PM, Continue reading at the source
The Medicines Company (MDCO) Q1 Loss Wider Than Expected Nasdaq - 15 hours ago In Nov last year, The Medicines Company and partner Alnylam Pharmaceuticals, Inc. ALNY announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran. The Medicines Company (MDCO) Rating Reiterated by Jefferies Group LLC - The Cerbat Gem The Medicines Company (MDCO) Moves Higher on Volume Spike for April 26 - Equities.com [...]
Thu, Apr 27, 2017 2:26:00 PM, Continue reading at the source
The Medicines Company (MDCO) Showcases What It Has To Offer Via The Technical ... NY Stock News - Apr 26, 2017 The Medicines Company (MDCO) has been having a set of eventful trading activity and it is clear from an examination of the charts that traders are now fully aware of the company's key metrics. [...]
Wed, Apr 26, 2017 6:22:00 PM, Continue reading at the source
BRIEF-The Medicines Company Q1 loss per share $1.44 Reuters - Apr 26, 2017 Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news ... [...]
Wed, Apr 26, 2017 11:48:00 AM, Continue reading at the source
The Medicines Company Reports First-Quarter 2017 Financial Results Yahoo Finance - Apr 26, 2017 The Medicines Company (MDCO) today announced its business and financial results for the first-quarter ended March 31, 2017. The Medicines Company granted approval for phase III trial of new heart drug - Proactive Investors USA & Canada The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA ... - Business Wire (press release) [...]
Wed, Apr 26, 2017 11:15:00 AM, Continue reading at the source
The Medicines Company (MDCO) PT Raised to $61 at Cowen Following Positive ... StreetInsider.com - Apr 19, 2017 Cowen analyst Chris Shibutani raised his price target on The Medicines Company (NASDAQ: MDCO) to $61.00 (from $39.00) while maintaining a Outperform rating after an ACC excerpt survey on Inclisiran. [...]
Wed, Apr 19, 2017 10:07:00 AM, Continue reading at the source
The Medicines Company to Announce First-Quarter 2017 Financial Results on ... Yahoo Finance - Apr 12, 2017 The Medicines Company is a biopharmaceutical company driven by an overriding purpose - to save lives, alleviate suffering and contribute to the economics of healthcare. Jefferies Group LLC Reiterates Buy Rating for The Medicines Company (MDCO) - The Cerbat Gem The Medicines Company (MDCO) Reaches $55.56 High on Apr, 11, Endurant Capital ... - HuronReport [...]
Wed, Apr 12, 2017 8:26:00 PM, Continue reading at the source
The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors Yahoo Finance - Mar 31, 2017 The Medicines Company (MDCO) today announced that it has appointed Paris Panayiotopoulos to its Board of Directors. Mr. Panayiotopoulos, who will serve as a Class I director, will stand for election at the Company's 2017 Annual Meeting of Stockholders. [...]
Fri, Mar 31, 2017 10:52:00 AM, Continue reading at the source
The Medicines Company to Present at Needham Healthcare Conference Yahoo Finance - Mar 30, 2017 The Medicines Company is a biopharmaceutical company driven by an overriding purpose - to save lives, alleviate suffering and contribute to the economics of healthcare. [...]
Thu, Mar 30, 2017 8:26:00 PM, Continue reading at the source